Case Report: Navigating the bleeding-thrombosis paradox: regional nafamostat anticoagulation in a post-intracerebral hemorrhage patient on VV-ECMO - Report - MDSpire
Advertisement
Case Report: Navigating the bleeding-thrombosis paradox: regional nafamostat anticoagulation in a post-intracerebral hemorrhage patient on VV-ECMO
Clinical Report: Addressing the Bleeding-Thrombosis Dilemma with Nafamostat
Overview
This case study explores the use of nafamostat mesylate for anticoagulation in a VV-ECMO patient post-intracerebral hemorrhage. A strategic adjustment in the infusion site was made.
Background
Extracorporeal membrane oxygenation (ECMO) is a critical intervention for patients with severe acute respiratory distress syndrome (ARDS), particularly following intracerebral hemorrhage (ICH). The challenge lies in balancing the risk of circuit thrombosis against the potential for rebleeding due to systemic anticoagulation. Current practices vary widely, and there is no standardized approach for anticoagulation in post-ICH patients on ECMO.
Data Highlights
No numerical data provided in the article.
Key Findings
Nafamostat mesylate (NM) was used for anticoagulation in a VV-ECMO patient post-ICH.
Initial NM infusion at the conventional post-pump site did not achieve regional anticoagulation.
Relocating the NM infusion to the pre-pump position established a circuit-to-systemic aPTT gradient.
This adjustment allowed for control of circuit thrombosis.
Clinical Implications
The findings indicate that the infusion site of anticoagulants like NM can impact coagulation outcomes in ECMO patients.
Conclusion
This case illustrates the adjustment of infusion techniques in VV-ECMO management.
